Jin Medical International Ltd. (ZJYL) Stock Price & Analysis
Jin Medical International Ltd. (ZJYL) is trading at USD 3.42, up 1.33% today, as of November 18, 2026 at 15:02 UTC (US market open; quotes may be delayed), according to Nexqual market data.
ZJYL last closed at USD 3.38; today's session has ranged USD 3.29–3.44 on volume of 1,843 shares. Market capitalization is $544.45M, with a 52-week range of USD 1.53–5.6 (NCM). Source: Nexqual, retrieved November 18, 2026 at 19:41 UTC.
What changed for ZJYL since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).
- Jin Medical International Ltd. (ZJYL) stock went from USD 14.22 (close of the week of Aug 25, 2025, split-adjusted) to USD 3.42, a -75.9% price change; the S&P 500 (SPY) moved +14.5% over the same period.
Also available as compact Markdown for AI agents: nexqual.com/ZJYL.md
Key facts (ZJYL)
- Analysts: None.
- Total return with dividends: 1Y -36.7% vs S&P 500 +11.6%; 5Y -54.1% vs S&P 500 +66.1%.
- Dividend: ZJYL paid no cash dividend in the last five years.
- Short interest: 0.01% of float (as of 2026-10-30), 0.0 days to cover.
Analysts (ZJYL)
Consensus None.
Total return (dividends reinvested) (ZJYL)
| 1Y (from 2025-11-18) | 5Y (from 2023-03-27) | |
|---|---|---|
| Total return | -36.7% | -54.1% |
| S&P 500 (SPY) | +11.6% | +66.1% |
| Per year | -36.7% | -19.2% |
| Volatility (annualized) | 112.1% | 161.9% |
| Max drawdown | -66.5% (Nov 2025→Jul 2026) | -99.3% (Jan 2024→Mar 2026) |
Dividends (ZJYL)
ZJYL paid no cash dividend in the last five years.
Short interest (ZJYL)
7,541 shares sold short, 0.01% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 70,013 shares (-89.2%). Days to cover: 0.0 (short shares ÷ average daily volume).
ZJYL major shareholder filing: Schedule 13D/A, Sep 25, 2026
Erqi Wang, JOLLY HARMONY ENTERPRISES Ltd filed a Schedule 13D/A with the SEC on Sep 25, 2026, reporting up to 3.35% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
The information set forth in Item 5 is hereby incorporated by reference into this Item 4. Item 4 is hereby amended and supplemented to add the following: This Amendment No. 1 is filed to report that the Reporting Persons' aggregate percentage beneficial ownership and voting power in the Issuer were diluted as a result of the Issuer's issuance of shares as described in Item 5 below.
Source: SEC EDGAR, Schedule 13D/A filed Sep 25, 2026. Quoted word for word; Nexqual adds no interpretation.
ZJYL recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 30, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 30, 2026 |
| Sep 25, 2026 | Schedule 13D/A | Erqi Wang, JOLLY HARMONY ENTERPRISES Ltd: 3.4% of shares, 5%+ holder that may seek to influence the company (amended) “The information set forth in Item 5 is hereby incorporated by reference into this Item 4. Item 4 is hereby amended and supplemented to add the following: This Amendment No. 1 is filed to report that the Reporting Persons' aggregate percentage beneficial ownership and voting…” |
| Sep 24, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 24, 2026 |
| Sep 8, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 8, 2026 |
| Aug 21, 2026 | Schedule 13D | Wang Erqi, JOLLY HARMONY ENTERPRISES Ltd: 6.8% of shares, 5%+ holder that may seek to influence the company “The information set forth in or incorporated by reference into Item 3 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 4. The transactions described in Item 3 were undertaken in connection with the Issuer's recapitalization and its…” |
| Aug 18, 2026 | Schedule 13G | NOVASTRALIST HORIZON LTD., Chang Gil LEE: 10.5% of shares, passive 5%+ holder |
| Aug 4, 2026 | 6-K | Current report (foreign issuer) · period ended Mar 31, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ZJYL suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Nissin Medical Industries | “We have one large customer, Nissin, with whom we generated substantial revenue each year.” |
Quoted from the company's 20-F filed Feb 10, 2026.
ZJYL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of November 18, 2026 at 19:41 UTC)
| Price | USD 3.42 |
|---|---|
| Change | ▲ 1.33% (up) |
| Previous Close | USD 3.38 |
| Open | USD 3.29 |
| Day Range | USD 3.29 – 3.44 |
| 52-Week Range | USD 1.53 – 5.6 |
| Volume | 1,843 shares |
| Market Cap | $544.45M |
| Exchange | NCM |
Technical Analysis (ZJYL)
Nexqual's technical model rates ZJYL "STRONG BUY" based on 5 bullish and 0 bearish signals across 129 daily candles, as of November 18, 2026 at 19:41 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.86 (neutral) |
| vs SMA50 | Above (USD 2.41) |
| MACD | 0.42 (positive) |
Analyst Ratings (ZJYL)
Wall Street analysts rate ZJYL "None", per Nexqual as of November 18, 2026 at 19:41 UTC.
| Consensus Rating | None |
|---|
Earnings (ZJYL)
Source: Nexqual, November 18, 2026 at 19:41 UTC.
Financials & Fundamentals (ZJYL)
| Total Revenue | $19.73M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -9.70% |
| Gross Margin | +31.28% |
| Operating Margin | +2.12% |
| Profit Margin | +5.95% |
| ROE | +4.02% |
| Debt / Equity | 0.69 |
| Current Ratio | 1.95 |
| Total Cash | $30.10M |
| Total Debt | $20.90M |
Source: Nexqual, November 18, 2026 at 19:41 UTC.
Financial Health Score (ZJYL)
Nexqual rates Jin Medical International Ltd.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 19:41 UTC.
| Growth | Weak — Revenue -10% YoY (latest Q), declining |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Solid — $30M cash vs $21M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$593K (TTM) |
| Efficiency | Weak — ROE 4%, ROA 0.5% |
Ownership (ZJYL)
| Insider Ownership | +11.97% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 153.43M |
| Float | 64.84M |
| Short % of Float | +0.01% |
Source: Nexqual, November 18, 2026 at 19:41 UTC.
Leadership (ZJYL)
Jin Medical International Ltd. is led by Erqi Wang, Chairman of the Board, President & CEO, per Nexqual as of November 18, 2026 at 19:41 UTC.
| Chairman of the Board, President & CEO | Erqi Wang |
|---|---|
| CFO & Director | Ziqiang Wang |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LMAT | LeMaitre Vascular, Inc. | USD 75.59 | ▼ 0.68% |
| AZTA | Azenta, Inc. | USD 47.5 | ▲ 3.68% |
| ATRC | AtriCure, Inc. | USD 55.83 | ▲ 1.46% |
| VVVV | vVARDIS Holding AG | USD 15.67 | ▼ 0.85% |
| WRBY | Warby Parker Inc. | USD 26.09 | ▲ 0.66% |
| PLSE | Pulse Biosciences, Inc | USD 44.6 | ▼ 0.54% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 19:41 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt